Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2021/04/033243
CTRI/2021/04/033243
Not yet recruiting
Phase 3

Clinical Study To Evaluate The Efficacy And Safety Of Psorlyn Tablet And Psorlyn Oil In Psoriasis W.S.R. Kitibha

DrVasishths Ayuremedies0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
DrVasishths Ayuremedies
Status
Not yet recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
DrVasishths Ayuremedies

Eligibility Criteria

Inclusion Criteria

  • •1\. Children age group between 10 ââ?¬â?? 16 years of either sex.
  • •2\. Children having classical sign and symptom and diagnosed as psoriasis.
  • •3\. Patient should be capable of obeying the instruction related to course of therapy.

Exclusion Criteria

  • •1\. Patient with k/c/o any chronic systemic illness and allergic disorders.
  • •2\. Patient with k/c/o any other chronic skin disorder except psoriasis.
  • •3\. Patient not fulfilling the inclusion criteria.
  • •4\. Patient/Attendant not willing to give written consent for participation in the research study.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 1
Evaluate The Efficacy And Safety Of HMTG-122106 In Childre
CTRI/2023/07/054858Himalaya Wellness Company
Not yet recruiting
Phase 1
To Evaluate The Efficacy And Safety Of HSGM-122104 Inchildren in (Healthy Human Volunteers)
CTRI/2023/07/054999Himalaya Wellness Company
Completed
Phase 2
TO Find the Effect of LION�S MANE CAPSULE as Nutritional SupplementHealth Condition 1: E089- Diabetes mellitus due to underlying condition without complications
CTRI/2022/03/040725DXN Manufacturing India Pvt Ltd24
Active, not recruiting
Not Applicable
Clinical Study to Evaluate the Efficacy and Safety of the Combination Therapy Candesartan Cilexetil 32 mg plus Hydrochlorothiazide 25 mg in Patients with Severe HypertensioSubjects with severe essential hypertension (SBP between 150 mmHg and 200 mmHg AND DBP between 110 mmHg and 120 mmHg) who did not receive any antihypertensive treatment before will be included in the studyMedDRA version: 9.1Level: LLTClassification code 10015488Term: Essential hypertension
EUCTR2009-011776-30-DETakeda Pharma GmbH100
Completed
Phase 2
TO Find the Effect of Codyceps Tablet as Nutritional SupplementHealth Condition 1: E089- Diabetes mellitus due to underlying condition without complications
CTRI/2022/03/040784DXN Manufacturing India Pvt Ltd24